Diosynth Biotechnology enters long-term commercial supply agreement with Dendreon

06-Mar-2006

Diosynth Biotechnology announced that it has entered into a long-term commercial supply agreement with Dendreon Corporation for the manufacture of the recombinant antigen component of PROVENGE (sipuleucel-T), Dendreon's investigational active cellular immunotherapy for prostate cancer. The product will be manufactured for market launch and commercial sale in the Diosynth Biotechnology state-of-the-art facility in North Carolina, US. Subsequent manufacturing may also be done at the large-scale cell culture facilities of Diosynth in the Netherlands.

This agreement reflects a continuing collaboration between Dendreon and Diosynth Biotechnology beginning with the initial agreement for process development and scale-up through the more recent manufacture of conformance lots.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances